Trastuzumab (herceptin): a retrospective analysis of the effects of long-term application in a series of patients with breast cancer.

Introduction: About 20 % of all mamma carcinomas are HER2 positive. The overexpression of HER2 is considered to be a negative prognostic factor. Trastuzumab is a monoclonal anti-HER2 antibody developed to target HER2 overexpressing tumor cells.

Can ki-67 play a role in prediction of breast cancer patients' response to neoadjuvant chemotherapy?

Background: Currently the choice of breast cancer therapy is based on prognostic factors. The proliferation marker Ki-67 is used increasingly to determine the method of therapy. The current study analyses the predictive value of Ki-67 in foreseeing breast cancer patients' responses to neoadjuvant chemotherapy.